Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|5|833-840

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.5, 2013-02, pp. : 833-840

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-12 ,pp. : 1284-1292

Bentham Science Publishers

Access to resources Recommend Favorite

The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 37, 2012-12 ,pp. : 6155-6168

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer

By  

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3933-3943

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors

By Danesi Romano   Altavilla Giuseppe   Giovannetti Elisa   Rosell Raffael  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 69-80

Future Medicine

Access to resources Recommend Favorite